U.S. officials say risk of locally acquired malaria remains low as nationwide cases jump to seven
The CDC and health experts say the new locally acquired cases in Florida and Texas shouldn’t warrant panic about widespread malaria transmission in the U.S.
Meta’s Twitter rival Threads explodes to 70 million signups one day after launch
The text-based social media product already has 70 million sign-ups, Meta CEO Mark Zuckerberg said on Friday.
Payrolls rose by 209,000 in June, less than expected, as jobs growth wobbles
Nonfarm payrolls were expected to increase by 240,000 and the unemployment rate to fall to 3.6% in June.
Morgan Stanley sees even more gains for Ferrari shares after strong 2023 start
Analyst Adam Jonas raised his price target on Ferrari shares to $340 from $310 while maintaining his overweight rating and top pick.
Rivian shares are set to pop more than 35% as outlook for EV maker improves, Wedbush says
Wedbush raised its price target on Rivian shares to $30 from $25 as the company’s production difficulties improve.
RBC says this stock can rally more than 50% thanks to strong demand for fuel cells
Analyst Chris Dendrinos initiated coverage of the electric and hydrogen power company with an outperform rating.
KeyBanc says this chip stock may struggle as positive catalysts remain uncertain
KeyBanc downgraded the stock to sector weight from overweight on account of the company’s shares recently exceeding its previous price target of $468.
Amazon CEO explains how the company will compete against Microsoft, Google in A.I. race
Amazon CEO Andy Jassy told CNBC the company has an edge in AI through its custom chips and services targeted for developers of large language models.
Microsoft CFO Amy Hood warned employees not to ‘build a gold toilet’
Microsoft was in fact working on a gold toilet, the CEO of gaming at Microsoft said in an email as the company was preparing to test cloud streaming.
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
